Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NateraMEX:NTRA 60 Gross Margin % is 64.71% as of Mar. 2026, which is 44% above its 10-year median of 44.95. GuruFocus rates MEX:NTRA with a GF Score™ of 60/100 and a GF Value™ of MXN2,983.49 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Natera ranks better than 69.59% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Natera's Gross Profit for the
three
months ended in Mar. 2026 was MXN8,130 Mil. Natera's Revenue for the
three
months ended in Mar. 2026 was MXN12,562 Mil. Therefore, Natera's Gross Margin % for the quarter that ended in Mar. 2026 was 64.71%.
The historical rank and industry rank for Natera's Gross Margin % or its related term are showing as below:
MEX:NTRA'
s Gross Margin % Range Over the Past 10 Years
Min: 33.41 Med: 44.95 Max: 65.07
Current: 65.07
During the past 13 years, the highestGross Margin % of Natera was 65.07%. The lowest was 33.41%. And the median was 44.95%.
MEX:NTRA's Gross Margin % is ranked better than 69.59% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs MEX:NTRA: 65.07
Natera had a gross margin of 64.71% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Natera was 6.30% per year.
Natera (MEX:NTRA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Natera had a gross margin of 64.71% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Natera Gross Margin % Related Terms
Natera Gross Margin % Historical Data
* Premium members only.
The historical data trend for Natera's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NTRA vs WAT, A, IQV: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Natera's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Natera's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Natera (MEX:NTRA) has a Gross Margin % of 64.71% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Natera and its competitors. This is 44% above median its historical median of 44.95. Over the past decade, Natera's Gross Margin % has ranged from 33.41 to 65.07. According to the industry distribution chart, Natera ranks #59 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 30.4%.
Is Natera's Gross Margin % too high?
Natera's current Gross Margin % of 64.71% is 44% above median its 10-year median of 44.95. Over the past 10 years, this metric has ranged from a low of 33.41 to a high of 65.07. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. Natera's value of 64.71% is 26.5% above this industry median. Based on the distribution chart, Natera ranks #59 out of 194 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Natera has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's Gross Margin % compare to WAT and A?
According to the Medical Diagnostics & Research industry distribution chart, Natera ranks #59 out of 194 companies for Gross Margin %. This puts Natera in the upper half of its industry. The industry median Gross Margin % is 51.14. Natera's value of 64.71% is 26.5% above this benchmark. Historically, Natera's own Gross Margin % has ranged from 33.41 to 65.07 over the past decade. While the company's 10-year median is 44.95 vs. the industry median of 51.14, Natera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natera's current Gross Margin % of 64.71% is 26.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Natera and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natera's current Gross Margin % is 64.71%, which is 44% above median its own 10-year median of 44.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (MEX:NTRA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,983.49, compared to a current price of MXN3,905.00 — trading 30.9% above its estimated fair value. The current Gross Margin % is 64.71%, which is 44% above median its 10-year median of 44.95 and 26.5% above the Medical Diagnostics & Research industry median of 51.14. Natera's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Natera (MEX:NTRA), the current Gross Margin % is 64.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natera (MEX:NTRA) Overvalued in 2026?
Based on GuruFocus' analysis, Natera stock appears to be overvalued.
The current stock price of MXN3,905.00 is trading 30.9% above its estimated GF Value™ of MXN2,983.49.
GuruFocus considers Natera to be Significantly Overvalued.
Key valuation signals for MEX:NTRA:
Gross Margin %: 64.71% (44% above median its 10-year median of 44.95)
GF Value™: MXN2,983.49 vs. price of MXN3,905.00 (30.9% above fair value)
Industry Position: 26.5% above the Medical Diagnostics & Research median (#59 of 194)
No single metric tells the full story. See the MEX:NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
60GF Score
Get the complete analysis for MEX:NTRA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NTRA has been successfully added to your 
